English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/169584
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Selective depletion of metastatic stem cells as therapy for human colorectal cancer

AutorCéspedes, María Virtudes; Unzueta, Uguntz; Aviñó, Anna; Gallardo, Alberto ; Alamo, Patricia; Sala, Rita; Sánchez-Chardi, Alejandro; Casanova, Isolda; Mangues, Maria Antònia; López-Pousa, Antonio; Eritja Casadellà, Ramón; Villaverde, Antonio; Vázquez, Ramón; Mangues, Ramón
Palabras claveColorectal cancer
CXCR4 receptor
Metastatic stem cells
Protein nanoconjugate
Targeted drug delivery
Fecha de publicación6-sep-2018
EditorEuropean Molecular Biology Organization
CitaciónEMBO Molecular Medicine e8772 (2018)
ResumenSelective elimination of metastatic stem cells (MetSCs) promises to block metastatic dissemination. Colorectal cancer (CRC) cells overexpressing CXCR4 display trafficking functions and metastasis‐initiating capacity. We assessed the antimetastatic activity of a nanoconjugate (T22‐GFP‐H6‐FdU) that selectively delivers Floxuridine to CXCR4+ cells. In contrast to free oligo‐FdU, intravenous T22‐GFP‐H6‐FdU selectively accumulates and internalizes in CXCR4+ cancer cells, triggering DNA damage and apoptosis, which leads to their selective elimination and to reduced tumor re‐initiation capacity. Repeated T22‐GFP‐H6‐FdU administration in cell line and patient‐derived CRC models blocks intravasation and completely prevents metastases development in 38–83% of mice, while showing CXCR4 expression‐dependent and site‐dependent reduction in foci number and size in liver, peritoneal, or lung metastases in the rest of mice, compared to free oligo‐FdU. T22‐GFP‐H6‐FdU induces also higher regression of established metastases than free oligo‐FdU, with negligible distribution or toxicity in normal tissues. This targeted drug delivery approach yields potent antimetastatic effect, through selective depletion of metastatic CXCR4+ cancer cells, and validates metastatic stem cells (MetSCs) as targets for clinical therapy.
Versión del editorhttps://doi.org/10.15252/emmm.201708772
URIhttp://hdl.handle.net/10261/169584
DOI10.15252/emmm.201708772
Aparece en las colecciones: (IQAC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Selective depletion of metastatic stem cells as.pdf7,3 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.